Valam (valsartan + amlodipine): Uses, Dosage & Side Effects

What it's for (Indications)

Valsartan + Amlodipine (e.
g.
, Valmo) is indicated for the treatment of essential hypertension.
This fixed-dose combination therapy is particularly suitable for patients whose blood pressure is not adequately controlled with either monotherapy (valsartan or amlodipine alone) or as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.
The combination leverages two distinct mechanisms of action to provide comprehensive blood pressure reduction: valsartan, an angiotensin II receptor blocker (ARB), and amlodipine, a dihydropyridine calcium channel blocker (CCB).
This synergistic effect often allows for better blood pressure control with fewer tablets, potentially enhancing patient adherence to treatment regimens.
It is crucial to individualize therapy based on the patient’s clinical response and tolerability, considering factors such as baseline blood pressure, comorbidities, and previous antihypertensive medication history.
Regular monitoring of blood pressure and assessment of kidney function and electrolytes are recommended during therapy.

Dosage Information

Type	Guideline
Standard	The dosage of Valsartan + Amlodipine must be individualized based on the patient's existing therapy, response, and tolerability. Typically, this medication is available in fixed-dose combination tablets containing various strengths of both valsartan and amlodipine. For patients whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy, the recommended starting dose is one tablet once daily, with the specific strength chosen based on the component doses the patient was previously receiving. If a patient is starting dual therapy, initial doses often begin with lower strengths of each component to assess tolerability, then titrated upwards every 1 to 2 weeks as needed to achieve target blood pressure. The maximum recommended daily dose is generally 320 mg of valsartan and 10 mg of amlodipine, taken as a single oral tablet once daily. It can be taken with or without food. Dosage adjustments may be necessary in patients with severe renal impairment (e.g., creatinine clearance <30 mL/min) or moderate to severe hepatic impairment, and careful monitoring is warranted in these populations. Adherence to the prescribed dosing regimen is vital for optimal therapeutic outcomes.

Type

Guideline

Standard

The dosage of Valsartan + Amlodipine must be individualized based on the patient's existing therapy, response, and tolerability. Typically, this medication is available in fixed-dose combination tablets containing various strengths of both valsartan and amlodipine. For patients whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy, the recommended starting dose is one tablet once daily, with the specific strength chosen based on the component doses the patient was previously receiving. If a patient is starting dual therapy, initial doses often begin with lower strengths of each component to assess tolerability, then titrated upwards every 1 to 2 weeks as needed to achieve target blood pressure. The maximum recommended daily dose is generally 320 mg of valsartan and 10 mg of amlodipine, taken as a single oral tablet once daily. It can be taken with or without food. Dosage adjustments may be necessary in patients with severe renal impairment (e.g., creatinine clearance <30 mL/min) or moderate to severe hepatic impairment, and careful monitoring is warranted in these populations. Adherence to the prescribed dosing regimen is vital for optimal therapeutic outcomes.

Safety & Warnings

Common Side Effects

The most common side effects associated with Valsartan + Amlodipine typically include peripheral edema (swelling of the ankles or feet), headache, dizziness, fatigue, and flushing.
These are generally mild to moderate in intensity and often dose-dependent, particularly for amlodipine-related effects.
Other reported side effects may include nasopharyngitis, upper respiratory tract infection, back pain, and nausea.
Less common but potentially serious adverse effects can occur.
Valsartan, as an ARB, may lead to hyperkalemia, renal impairment or failure, and rarely, angioedema.
Amlodipine, while generally well-tolerated, can sometimes cause palpitations or, in very rare instances, an exacerbation of angina or acute myocardial infarction, especially at the initiation of treatment or during dose escalation in patients with severe obstructive coronary artery disease.
Patients should be advised to report any persistent or worsening side effects, or any signs of more severe reactions such as difficulty breathing, severe swelling of the face, lips, tongue, or throat (angioedema), or signs of liver problems (e.
g.
, unexplained fatigue, dark urine, yellowing of skin or eyes).

Serious Warnings

Black Box Warning: **FETAL TOXICITY:** Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Valsartan + Amlodipine contains valsartan, an angiotensin II receptor blocker (ARB), and therefore, use during the second and third trimesters of pregnancy is contraindicated. If pregnancy is detected, Valsartan + Amlodipine should be discontinued as soon as possible. Exposure to ARBs during the second and third trimesters is known to cause fetal injury, including oligohydramnios, fetal skull hypoplasia, anuria, renal failure, hypotension, and death. Neonatal complications can include anuria, hypotension, hyperkalemia, and oliguria. While exposure to ARBs during the first trimester is not associated with an increased risk of birth defects, treatment with ARBs should be discontinued as soon as pregnancy is detected. Healthcare providers should discuss the potential risks to the fetus with women of childbearing potential and ensure appropriate contraceptive measures are in place or alternative antihypertensive treatments are considered if pregnancy is planned.
Valsartan + Amlodipine therapy requires careful consideration due to several significant warnings.
**Hypotension** may occur, particularly in patients who are volume-depleted (e.
g.
, those on high-dose diuretics or with severe sodium restriction).
Correcting volume and/or sodium depletion prior to initiating therapy or starting with a lower dose is recommended.
**Renal Impairment** can be exacerbated, especially in patients whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system (e.
g.
, patients with severe congestive heart failure, renal artery stenosis).
Close monitoring of renal function, including serum creatinine and blood urea nitrogen (BUN), is advised.
**Hyperkalemia** may develop, particularly in patients with renal dysfunction, diabetes mellitus, or those concurrently taking potassium-sparing diuretics, potassium supplements, or other agents that increase potassium levels (e.
g.
, trimethoprim-sulfamethoxazole, heparin).
**Hepatic Impairment** requires caution, as valsartan is extensively metabolized in the liver, and amlodipine is also metabolized in the liver.
Dosage adjustments and careful monitoring are necessary in these patients.
In patients with severe obstructive coronary artery disease, initiation of amlodipine or dosage increases may rarely precipitate an increase in frequency, duration, or severity of angina or acute myocardial infarction.
The combination should be used with caution in patients with severe aortic stenosis or hypertrophic obstructive cardiomyopathy.
Patients should be educated on the potential risks and symptoms requiring immediate medical attention.

How it Works (Mechanism of Action)

Valsartan + Amlodipine exerts its antihypertensive effects through a dual mechanism involving two distinct pharmacological classes. **Valsartan** is an angiotensin II receptor blocker (ARB). It selectively blocks the binding of angiotensin II to the AT1 receptor, which is responsible for the vasoconstrictive, aldosterone-secreting, and cell-proliferative effects of angiotensin II. By blocking this receptor, valsartan leads to vasodilation, reduction of aldosterone secretion (thereby decreasing sodium and water reabsorption), and inhibition of cardiac and vascular remodeling, ultimately resulting in a decrease in blood pressure. **Amlodipine** is a dihydropyridine calcium channel blocker (CCB). It inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle cells. This inhibition leads to the relaxation of vascular smooth muscle, particularly in the peripheral arterioles, causing peripheral vasodilation and a reduction in total peripheral vascular resistance. The combined effect of reduced vasoconstriction from valsartan and direct peripheral vasodilation from amlodipine provides a potent and complementary antihypertensive action, leading to effective and sustained blood pressure reduction.